A study of MTX110 for the treatment of the fatal childhood brain cancer DIPG

Trial Profile

A study of MTX110 for the treatment of the fatal childhood brain cancer DIPG

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2018

At a glance

  • Drugs MTX 110 (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jan 2018 New trial record
    • 16 Jan 2018 According to a Midatech Pharma US media release, successful data of this trial will be used for approval of the drug from international regulators.
    • 16 Jan 2018 According to a Midatech Pharma US media release, this trial will be conducted at centres in UCSF in San Francisco, and the Memorial Sloan Kettering Cancer Center in New York. First treatment in patients expected in Q1 2018. Read out from this trial expected towards the end of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top